An analytical review on method development and validation of drugs used for alzheimers disease

Sivagami B, Chandrasekar R, Pavan Kumar V, Sireesha R, Reddy Padmaja B


Alzheimers disease (AD) is a neurodegenerative disorder characterized by progressive memory defeat and impairment in behavior, language, and visuospatial skills. Current approved drugs for the treatment of Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, galantamine and rivastigmine,) and the NMDA receptor antagonist memantine. These drugs can provide a symptomatic relief but they poorly affect the progression of the disease. There are several risk factors for the development of Alzheimers disease which include factors like age, genetic factor family history, Downs syndrome, head injury and cardiovascular diseases. Cardio vascular risk factors may include blood pressure, cholesterol, diabetes, obesity and smoking. People may experience cognitive mental illness, difficulty in understanding and thinking, forgetting things easily, making things complicated, mental confusion, difficulty in concentrating, inability to create old memories, inability to do simple things, or inability to recognize common things. The main objective of this review is discussion on various analytical methods used, different solvents used as mobile phase and their retention time. This review includes method development and validation of cholinesterase inhibitors like Donepezil, Galantamine, Rivastigmine and Tacrine combination of drugs which include cholinesterase inhibitors like Donepezil and NMDA receptor antagonist Memantine. The review is a collection of data including various analytical methods used, the different columns used, mobile phase used, flow rate, different detectors and detection wavelength and retention time. This review includes discussion on method development and validation of Alzheimers drugs and newly developed compounds which have lesser side effects and are proving more efficient for treatment of Alzheimers disease.


Alzheimers Disease, Cholinesterase inhibitors, Dementia, Method Development, Validation.

Full Text:




  • There are currently no refbacks.

Copyright (c) 2017 International Journal of Advances in Pharmaceutical Analysis